Suppressive Dose of Valacyclovir
For immunocompetent adults without renal impairment, the standard suppressive dose of valacyclovir is 500 mg to 1000 mg once daily, with 1000 mg once daily preferred for patients with 10 or more recurrences per year. 1
Dosing Algorithm by Patient Population
Immunocompetent Adults (Normal Renal Function)
Standard suppression:
- 500 mg once daily for patients with fewer than 10 recurrences per year 1
- 1000 mg once daily for patients with 10 or more recurrences per year 1
Alternative regimens (all equally effective):
- 250 mg twice daily 1
- Note: 500 mg once daily appears less effective than other regimens in patients with very frequent recurrences (≥10 episodes per year) 1
HIV-Infected Adults
For HIV-infected patients, use 500 mg twice daily (not once daily dosing) 1. This higher dose is specifically recommended because HIV-infected individuals require increased dosing compared to immunocompetent patients 1. The once-daily regimens used in immunocompetent patients are insufficient for this population.
Renal Impairment Adjustments
Dose reduction is mandatory for renal impairment 2:
- CrCl 30-49 mL/min: No reduction needed for suppressive therapy 2
- CrCl 10-29 mL/min: 500 mg every 24 hours 2
- CrCl <10 mL/min: 500 mg every 24 hours 2
- Hemodialysis: Administer after dialysis session 2
Clinical Efficacy Evidence
Suppressive therapy reduces recurrence frequency by ≥75% in patients with frequent recurrences (≥6 per year) 1. Research demonstrates that 500 mg once daily prevented or delayed 85% of recurrences compared to placebo over 16 weeks 3. In a large dose-ranging study, all valacyclovir dosages (250 mg to 1000 mg daily) were significantly more effective than placebo, with a clear dose-response relationship across once-daily regimens 4.
Duration of therapy: Safety and efficacy have been documented for up to 6 years with acyclovir and 1 year with valacyclovir 1. After 1 year of continuous suppressive therapy, reassess the patient to determine if continued suppression is needed, as recurrence frequency often decreases over time 1.
Important Safety Considerations
Monitor for thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) in HIV-infected patients, particularly at high doses (8 grams/day), though this has not been reported at standard suppressive doses 1.
Common adverse effects include nausea and headache, which are occasional and generally mild 1. No laboratory monitoring is required for patients on suppressive therapy unless substantial renal impairment exists 1.
Neurotoxicity risk exists in patients with severe renal impairment, particularly those on dialysis, even at apparently safe doses 5. Symptoms can include mental confusion, hallucinations, ataxia, and dysarthria, appearing 2-4 days after treatment initiation 5.
Common Pitfalls to Avoid
- Do not use 500 mg once daily in patients with ≥10 recurrences per year—this dose is less effective in this population 1
- Do not use once-daily dosing in HIV-infected patients—they require 500 mg twice daily 1
- Do not forget renal dose adjustments—failure to adjust for renal impairment can lead to neurotoxicity 2, 5
- Do not confuse suppressive dosing with episodic treatment dosing—episodic treatment uses much higher doses (500 mg twice daily for 5 days or 2 grams twice daily for 1 day) 1